The presence of KIR2DS5 confers protection against adult immune thrombocytopenia

Tissue Antigens

Volumn 83, Issue 3, 2014, Pages 154-160

  Seymour, L A ^a,b,c   Nourse, J P ^c   Crooks, P ^a,c   Wockner, L ^c   Bird, R ^a,b   Tran, H ^d   Gandhi, M K ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

Author keywords

Genetic association; Immune thrombocytopenia; ITP; Killer cell immunoglobulin like receptors

Indexed keywords

GENETIC ASSOCIATION; IMMUNE THROMBOCYTOPENIA; ITP; KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTORS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HLA-C ANTIGENS; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; ODDS RATIO; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, KIR; YOUNG ADULT;

EID: 84894247642     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12295     Document Type: Article

References (32)

1. Abdel-Hamid SM, Al-Lithy HN. B cell activating factor gene polymorphisms in patients with risk of idiopathic thrombocytopenic purpura. Am J Med Sci 2011: 342: 9-14.
2. Nourse JP, Lea R, Crooks P et al. The KIR2DS2/2DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms. Blood Coagul Fibrinolysis 2012: 23: 45-50.
3. Olsson B, Andersson P-O, Jernarings M et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003: 9: 1123-4.
4. Martin MP, Nelson G, Lee J-H et al. Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 2002: 169: 2818-22.
5. Van der Slik AR, Koeleman BPC, Verduijn W, Bruining GJ, Roep BO, Giphart MJ. KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes 2003: 52: 2639-42.
6. Nikitina-Zake L, Rajalingham R, Rumba I, Sanjeevi CB. Killer cell immunoglobulin-like receptor genes in Latvian patients with type 1 diabetes mellitus and healthy controls. Ann N Y Acad Sci 2004: 1037: 161-9.
7. Momot T, Koch S, Hunzelmann N et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 2004: 50: 1561-5.
8. García-León JA, Pinto-Medel MJ, García-Trujillo L et al. Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients. Mol Immunol 2011: 48: 1896-902.
9. Jelčić I, Hsu KC, Kakalacheva K et al. Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis. Mult Scler 2012: 18: 951-8.
10. Hiby SE, Walker JJ, O'shaughnessy KM et al. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004: 200: 957-65.
11. Alter G, Martin MP, Teigen N et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007: 204: 3027-36.
12. Martin MP, Gao X, Lee J-H et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002: 31: 429-34.
13. Suppiah V, Gaudieri S, Armstrong NJ et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis c virus infection in a European cohort: a cross-sectional study. PLoS Med 2011: 8.
14. Naumova E, Mihaylova A, Stoitchkov K, Ivanova M, Quin L, Toneva M. Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother 2005: 54: 172-8.
15. Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfus 2011: 9: 262-73.
16. Hatjiharissi E, Xu L, Santos DD et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcγRIIIa-158 V/V and V/F polymorphism. Blood 2007: 110: 2561-4.
17. George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996: 88: 3-40.
18. Rodeghiero F, Stasi R, Gernsheimer T et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an International Working Group. Blood 2009: 113: 2386-93.
19. Keen-Kim D, Mathews CA, Reus VI et al. Overrepresentation of rare variants in a specific ethnic group may confuse interpretation of association analyses. Hum Mol Genet 2006: 15: 3324-8.
20. Ashouri E, Ghaderi A, Reed EF, Rajalingam R. A novel duplex SSP-PCR typing method for KIR gene profiling. Tissue Antigens 2009: 74: 62-7.
21. Maxwell LD, Ross OA, Curran MD, Rea IM, Middleton D. Investigation of KIR diversity in immunosenescence and longevity within the Irish population. Exp Gerontol 2004: 39: 1223-32.
22. Gourraud P-A, Meenagh A, Cambon-Thomsen A, Middleton D. Linkage disequilibrium organization of the human KIR superlocus: implications for KIR data analyses. Immunogenetics 2010: 62: 729-40.
23. Carrington M, Norman P. The KIR gene cluster [Internet]. 2003 [cited 10 February 2013]. http://www.ncbi.nlm.nih.gov/books/NBK10134/#A27
24. Nowak I, Majorczyk E, Wiśniewski A et al. Does the KIR2DS5 gene protect from some human diseases? PLoS One 2010: 5.
25. Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004: 305: 872-4.
26. Middleton D, Gonzelez F. The extensive polymorphism of KIR genes. Immunology 2010: 129: 8-19.
27. Howe EC, Wlodarski M, Ball EJ, Rybicki L, Maciejewski JP. Killer immunoglobulin-like receptor genotype in immune-mediated bone marrow failure syndromes. Exp Hematol 2005: 33: 1357-62.
28. Van der Meer A, Schaap NPM, Schattenberg AVMB, van Cranenbroek B, Tijssen HJ, Joosten I. KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients. Mol Immunol 2008 Aug: 45: 3631-8.
29. Rajagopalan S, Long EO. Understanding how combinations of HLA and KIR genes influence disease. J Exp Med 2005: 201: 1025-9.
30. Uhrberg M, Valiante NM, Shum BP et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997: 7: 753-63.
31. Mandelboim O, Kent S, Davis DM et al. Natural killer activating receptors trigger interferon gamma secretion from T cells and natural killer cells. Proc Natl Acad Sci U S A 1998: 95: 3798-803.
32. Borgerding A, Hasenkamp J, Engelke M et al. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression. Exp Hematol 2010: 38: 213-21.